Clinical trial • Phase III • Haematology

Brentuximab for Diffuse large B-cell lymphoma|Lymphoma

Phase III trial of Brentuximab for Diffuse large B-cell lymphoma|Lymphoma. 20 participants.

Overview

Trial Therapeutic Area
Haematology
Trial Disease
Diffuse large B-cell lymphoma|Lymphoma
Trial Stage
Phase III
Drug Modality
Monoclonal antibody|Radiopharmaceutical

Key dates

Initial CTIS Submission Date
15-10-2024
First CTIS Authorization Date
25-11-2024

Trial design

Phase III trial across 1 site in Netherlands.

Target Sample Size
20

Eligibility

Recruits 20 No vulnerable population selected (isVulnerablePopulationSelected=false). No information on consent or assent handling available..

Vulnerable Population
No vulnerable population selected (isVulnerablePopulationSelected=false). No information on consent or assent handling available.

Recruitment

Planned Sample Size
20
Recruitment Window Months
37

Geography

Total Number Of Sites
1
Total Number Of Participants
20

Netherlands

Earliest CTIS Part Ii Submission Date
15-10-2024
Latest Decision Or Authorization Date
25-11-2024
Processing Time Days
41
Number Of Sites
1
Number Of Participants
20

Sites

Site Name
Universitair Medisch Centrum Groningen
Department Name
Hematology
Contact Person Name
Marcel Nijland
Contact Person Email
m.nijland@umcg.nl

Sponsor

Primary sponsor

Full Name
Universitair Medisch Centrum Groningen
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Investigational products

Investigational Product Name
Zirconium-89-labeled Brentuximab
Active Substance
Brentuximab
Modality
Monoclonal antibody|Radiopharmaceutical

Related trials

Other published trials that may interest you.